ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent
Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!